Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04049630
Other study ID # EOLoa/LEV
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 16, 2021
Est. completion date July 15, 2021

Study information

Verified date September 2021
Source Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.


Description:

This clinical trial will be conducted in Republic of Congo. This is a pragmatic and adaptative randomized, double-blind clinical trial. Levamisole will be tested at 1 and 1,5 mg/kg, and compared to placebo (36:36:36); or 2,5 mg/kg compared to placebo (36:36) in case of adaptation of the dose for cohorts II and III. We will perform three cohorts of patients according to the microfilarial density : 1-1,999 mf/ml, 1-14,999 mf/ml, and all microfilaremic individuals; in order to respect the safety potentially related to loiasis. The first cohort was to evaluate the most appropriate dose of levamisole, with a possibility to increase (to 2.5 mg/kg) the dose of levamisole for the cohorts II and III in case of lack of efficacy and in case of good safety profil.


Recruitment information / eligibility

Status Completed
Enrollment 255
Est. completion date July 15, 2021
Est. primary completion date April 24, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Written consent written, signed (or with thumbprint) and dated - Aged 18 to 65 inclusive - Individual microfilarial density = 1mf/mL - Body weight = 40 kg in women and = 45 kg in men; and less than 85 kg - In good health condition, as determined by the medical questionnaire and the general clinical examination: absence of acute or chronic infection Exclusion Criteria: - Participation in any study other than purely observational, in the 4 weeks preceding this study (determined by the theoretical date of administration of LEV or placebo). - Any vaccination in the 4 weeks preceding this study. - Acute infection requiring a treatment in the 10 days preceding this study, determined by the anamnesis during the medical interview (example: pulmonary infection, ENT, digestive, cutaneous, with implementation of an antibiotic treatment or not) - Warfarin treatment - Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term treatment, or a treatment given in a single dose 10 days before the start of treatment for the clinical trial (precaution of use compared to the risk of agranulocytosis of immuno-allergic or toxic origin) - Known immunosuppressive pathology - Past or current history of neurological (including epilepsy) or neuropsychiatric disease - History of agranulocytosis - Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours preceding the administration of the treatment of the test determined by the anamnesis during the medical interview - Any condition, in the opinion of the investigator, which exposes the subject to an undue risk - Known intolerance to levamisole - Subjects who gave blood in the 8 weeks before entry into the study, with a standard volume (> 500 mL) - During the clinical examination: symptoms, physical signs or biological constants suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to interfere with the interpretation results of the test. The doctor may then give a favorable or unfavorable opinion for the inclusion of the participant - Taking IVM and / or LEV during the last six months; and / or mebendazole or albendazole in the last month - Pregnant and lactating women (based on self-declaration)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LEV 1 mg/kg
A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
LEV 1,5 mg/kg
A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
LEV 2,5 mg/kg
A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Placebo
5 tablets of placebo will be administrated to the participants.

Locations

Country Name City State
Congo Secteur opérationnelle de la Santé, Ministère de la Santé et de la Population Sibiti

Sponsors (1)

Lead Sponsor Collaborator
Programme National de Lutte contre l'Onchocercose, Republic of the Congo

Country where clinical trial is conducted

Congo, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of levamisole Absence of severe adverse events during the first week 1 week
Primary Incidence of adverse events with levamisole Proportion of adverse events during the first week 1 week
Secondary Efficacy of levamisole Proportion of reduction of the microfilarial density of Loa loa at Day 2, Day 7, and Month 1 Day 2, Day 7, and Month 1
Secondary Proportion of individuals without microfilariae of Loa loa Proportion of individuals with a diminution of 40% and 80% and more of the microfilarial density at Day 7 and Month 1 Day 7 and 1 Month
See also
  Status Clinical Trial Phase
Terminated NCT02644525 - Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Phase 2
Not yet recruiting NCT04035174 - Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa N/A
Completed NCT05085665 - Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events Phase 4
Active, not recruiting NCT04258670 - Spontaneous Antigenemia in Loiasis
Active, not recruiting NCT04049851 - Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Phase 2
Not yet recruiting NCT06350851 - Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination N/A
Completed NCT01111305 - Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Phase 2
Not yet recruiting NCT06252961 - A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects Phase 2/Phase 3